Novo Nordisk's Two-Speed Reality: Global Pipeline Accelerates While the Share Price Stalls

Novo Nordisk expands oral Wegovy globally, but US price cuts and analyst splits drag shares down 8.9% YTD.

There is a peculiar disconnect at the heart of Novo Nordisk's current story. On one side, the Danish pharmaceutical giant is methodically rolling out its oral weight-loss pill across new markets, filing for approvals in Asia, and launching in the European Union. On the other, its stock has spent much of 2026 drifting lower, weighed down by pricing concessions in its most profitable territory and a rare split among analysts over where the company goes next.

The Pill's Global March

The expansion of oral Wegovy continues apace. China accepted the regulatory filing for the tablet in late August, while South Korea greenlit three Phase 3 trials for Zenagamtide — the candidate formerly known as Amycretin. The Netherlands is slated to receive the pill by the end of September, and Germany became the first EU market to launch the oral semaglutide formulation last Friday, a move that handed Novo Nordisk a strategic edge over rival Eli Lilly in Europe.

That Germany launch, however, barely registered in the share price — a telling sign that investors are looking past pipeline milestones toward something more fundamental.

The Price of US Access

The core tension is straightforward: the United States remains Novo Nordisk's dominant market, but it is also where margins are shrinking most visibly. Reuters has reported that the company agreed in November to cut US prices for its semaglutide products across Medicare, Medicaid, and a direct-to-consumer channel. Through the planned TrumpRx platform, Ozempic and Wegovy will cost $350 per month — down from $1,000 and $1,350 respectively — while NovoLog and Tresiba are set at $35 monthly.

That structural repricing collides with another development that cuts both ways. A US appeals court, siding with Eli Lilly, upheld the FDA's determination that shortages of Ozempic, Wegovy, Mounjaro, and Zepbound have ended. The immediate reading favors the original manufacturers: the end of scarcity means the end of exemptions that had allowed cheaper copycat versions to circulate. But it also removes the artificial buffer that had softened direct competition between the two pharma heavyweights, which will now slug it out under normal regulatory pricing pressure.

A New Demographic Enters the Debate

Adding another layer of complexity, Reuters reported on Friday that prescriptions for weight-loss injections among American children under twelve have surged more than 300-fold since 2019. Wegovy was the most commonly prescribed Novo Nordisk product in that age group. For investors, the statistic is sensitive terrain — it reignites public scrutiny over how these highly sought-after medications are dispensed and could invite regulatory attention if the trend persists or triggers political pushback.

Analysts at Loggerheads

Seldom has the analyst community been so divided on Novo Nordisk. JPMorgan raised its price target to 275 Danish kroner in late August while maintaining a Neutral rating — an upward tweak, not an endorsement. The bank reaffirmed that stance on September 3 after management meetings, noting the company highlighted the oral Wegovy launch as a key milestone. AlphaValue/Baader also lifted its target without disclosing a specific figure.

On the same day, Deutsche Bank took the opposite tack, downgrading the stock to Sell with a 265-kroner target, citing uncertainty ahead of the capital markets day and arguing that Ziltivekimab — after missing a late-stage study goal — is effectively out of the running. Baptista Research went further still, executing a rare double downgrade straight from Buy to Sell. Three houses, three nearly contradictory signals within days.

Reading the Tape

The market's verdict is visible in the price action. The stock closed Friday at €40.09, down 1.8 percent on the day, though it still managed a 2.8 percent gain over the trailing week. Year-to-date, the shares have shed 8.9 percent — or 9.7 percent depending on the reference point — and they sit roughly 27 percent below the 52-week high of €54.86 notched in January.

That gap between operational momentum and share price performance is less contradictory than it appears. Capital markets do not reward approvals; they reward margins. And margins are precisely what the US pricing concessions threaten.

What September's Capital Markets Day May Resolve

All roads now lead to September 21, when Novo Nordisk hosts its capital markets day and management is expected to lay out its medium-term strategy. For investors, that will be the moment of truth: can the company credibly square global expansion with shrinking US profitability?

In the background, a quieter transition is underway. Myriam Mezher took over as managing director for Greece and Cyprus on September 1, succeeding Olympios Papadimitriou after his 32-year tenure. A small sign of continuity at a company otherwise being re-measured — caught between world markets and Wall Street's expectations.